Symbols / SNOA $2.44 +1.64%
SNOA Chart
About
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 4.22M |
| Enterprise Value | 2.26M | Income | -3.37M | Sales | 17.72M |
| Book/sh | 1.98 | Cash/sh | 1.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -4.36 | PEG | — |
| P/S | 0.24 | P/B | 1.23 | P/C | — |
| EV/EBITDA | -0.86 | EV/Sales | 0.13 | Quick Ratio | 1.21 |
| Current Ratio | 2.88 | Debt/Eq | 19.09 | LT Debt/Eq | — |
| EPS (ttm) | -1.95 | EPS next Y | -0.56 | EPS Growth | — |
| Revenue Growth | 22.00% | Earnings | 2026-02-10 16:00 | ROA | -12.67% |
| ROE | -81.18% | ROIC | — | Gross Margin | 38.16% |
| Oper. Margin | -15.59% | Profit Margin | -19.02% | Shs Outstand | 1.73M |
| Shs Float | 1.71M | Short Float | 0.98% | Short Ratio | 0.88 |
| Short Interest | — | 52W High | 6.92 | 52W Low | 1.75 |
| Beta | 1.70 | Avg Volume | 16.06K | Volume | 14.02K |
| Target Price | $12.00 | Recom | None | Prev Close | $2.40 |
| Price | $2.44 | Change | 1.64% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$12.00
Mean price target
2. Current target
$2.40
Latest analyst target
3. DCF / Fair value
$-37.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.40
Low
$12.00
High
$12.00
Mean
$12.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-05 | init | Ladenburg Thalmann | — → Buy | $3 |
| 2018-03-06 | down | Maxim Group | Buy → Hold | — |
| 2017-12-28 | init | Benchmark | — → Speculative Buy | $10 |
| 2017-11-10 | main | Maxim Group | — → Buy | $11 |
- Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - Yahoo Finance ue, 19 Aug 2025 07
- US revenue jumps 98% as Sonoma expands hypochlorous acid line - Stock Titan ue, 10 Feb 2026 08
- Sonoma Pharmaceuticals stock soars after diaper rash product hits Walmart - Investing.com hu, 14 Aug 2025 07
- SNOA Technical Analysis & Price Forecast - Intellectia AI hu, 12 Mar 2026 18
- Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st Wed, 14 Jan 2026 08
- Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum - Yahoo Finance Mon, 14 Jul 2025 07
- Will Sonoma Pharma’s New Product Boost Its Stock? - StocksToTrade hu, 14 Aug 2025 07
- Sonoma's First Major Consumer Product Hits Walmart Shelves: New Tech-Based Diaper Rash Treatment - Stock Titan Wed, 13 Aug 2025 07
- Aug Sentiment: What chart patterns are forming on SNOA - 2026 Technical Patterns & Weekly Stock Performance Updates - baoquankhu1.vn Mon, 16 Mar 2026 23
- Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut - Yahoo Finance hu, 14 Aug 2025 07
- SNOA Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 01
- What is the current Price Target and Forecast for Sonoma Pharmaceuticals (SNOA) - Zacks Investment Research ue, 03 Sep 2024 07
- SNOA Stock Price and Chart — NASDAQ:SNOA - TradingView Fri, 21 Jul 2017 23
- Sonoma Pharmaceuticals Stock Price Forecast. Should You Buy SNOA? - StockInvest.us hu, 10 Dec 2020 04
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace Mon, 12 Aug 2024 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 53586 | — | — | Stock Award(Grant) at price 0.00 per share. | DVONCH JEROME J | Chief Financial Officer | — | 2024-06-20 00:00:00 | D |
| 1 | 53586 | — | — | Stock Award(Grant) at price 0.00 per share. | TROMBLY AMY MOSS | Chief Executive Officer | — | 2024-06-20 00:00:00 | D |
| 2 | 53586 | — | — | Stock Award(Grant) at price 0.00 per share. | THORNTON BRUCE | Officer | — | 2024-06-20 00:00:00 | D |
| 3 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | DAL POGGETTO JOHN | Officer | — | 2024-06-20 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 54.13K |
| TaxRateForCalcs | 0.21 | 0.04 | 0.01 | 0.06 |
| NormalizedEBITDA | -3.57M | -4.53M | -4.45M | -6.57M |
| TotalUnusualItems | 1.00K | 873.00K | 137.00K | |
| TotalUnusualItemsExcludingGoodwill | 1.00K | 873.00K | 137.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.46M | -4.83M | -5.15M | -5.09M |
| ReconciledDepreciation | 138.00K | 176.00K | 125.00K | 186.00K |
| ReconciledCostOfRevenue | 8.82M | 7.99M | 8.79M | 8.63M |
| EBITDA | -3.57M | -4.53M | -4.45M | -5.70M |
| EBIT | -3.71M | -4.70M | -4.57M | -5.89M |
| NetInterestIncome | 16.00K | -10.00K | 4.00K | |
| InterestExpense | 12.00K | |||
| InterestIncome | 16.00K | |||
| NormalizedIncome | -3.46M | -4.83M | -5.15M | -5.90M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.46M | -4.83M | -5.15M | -5.09M |
| TotalExpenses | 18.00M | 17.44M | 17.84M | 18.52M |
| TotalOperatingIncomeAsReported | -3.71M | -4.70M | -4.57M | -5.89M |
| DilutedAverageShares | 1.24M | 455.00K | 169.70K | 132.65K |
| BasicAverageShares | 1.24M | 455.00K | 169.70K | 132.65K |
| DilutedEPS | -2.79 | -10.63 | -30.40 | -38.40 |
| BasicEPS | -2.79 | -10.63 | -30.40 | -38.40 |
| DilutedNIAvailtoComStockholders | -3.46M | -4.83M | -5.15M | -5.09M |
| NetIncomeCommonStockholders | -3.46M | -4.83M | -5.15M | -5.09M |
| NetIncome | -3.46M | -4.83M | -5.15M | -5.09M |
| NetIncomeIncludingNoncontrollingInterests | -3.46M | -4.83M | -5.15M | -5.09M |
| NetIncomeDiscontinuousOperations | 0.00 | 665.00K | ||
| NetIncomeContinuousOperations | -3.46M | -4.83M | -5.15M | -5.09M |
| TaxProvision | 550.00K | -196.00K | -33.00K | -332.00K |
| PretaxIncome | -2.91M | -5.03M | -5.18M | -5.42M |
| OtherIncomeExpense | 803.00K | -330.00K | -614.00K | 479.00K |
| OtherNonOperatingIncomeExpenses | 803.00K | -330.00K | -614.00K | -394.00K |
| SpecialIncomeCharges | 1.00K | 873.00K | 137.00K | |
| GainOnSaleOfPPE | 1.00K | 150.00K | 137.00K | |
| OtherSpecialCharges | -723.00K | |||
| NetNonOperatingInterestIncomeExpense | 16.00K | -10.00K | 4.00K | |
| TotalOtherFinanceCost | -16.00K | 10.00K | -4.00K | |
| InterestExpenseNonOperating | 12.00K | |||
| InterestIncomeNonOperating | 16.00K | |||
| OperatingIncome | -3.71M | -4.70M | -4.57M | -5.89M |
| OperatingExpense | 9.18M | 9.45M | 9.05M | 9.88M |
| ResearchAndDevelopment | 1.81M | 1.87M | 207.00K | 125.00K |
| SellingGeneralAndAdministration | 7.36M | 7.58M | 8.84M | 9.76M |
| GrossProfit | 5.46M | 4.75M | 4.48M | 3.99M |
| CostOfRevenue | 8.82M | 7.99M | 8.79M | 8.63M |
| TotalRevenue | 14.29M | 12.73M | 13.27M | 12.63M |
| OperatingRevenue | 14.29M | 12.73M | 13.27M | 12.63M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.63M | 780.37K | 246.68K | 155.05K |
| ShareIssued | 1.63M | 780.37K | 246.68K | 155.05K |
| TotalDebt | 305.00K | 608.00K | 849.00K | 1.37M |
| TangibleBookValue | 4.41M | 6.14M | 7.98M | 8.70M |
| InvestedCapital | 4.63M | 6.46M | 8.41M | 9.51M |
| WorkingCapital | 8.55M | 8.83M | 10.08M | 10.61M |
| NetTangibleAssets | 4.41M | 6.14M | 7.98M | 8.70M |
| CapitalLeaseObligations | 85.00K | 285.00K | 418.00K | 559.00K |
| CommonStockEquity | 4.41M | 6.14M | 7.98M | 8.70M |
| TotalCapitalization | 4.41M | 6.14M | 7.98M | 8.70M |
| TotalEquityGrossMinorityInterest | 4.41M | 6.14M | 7.98M | 8.70M |
| StockholdersEquity | 4.41M | 6.14M | 7.98M | 8.70M |
| GainsLossesNotAffectingRetainedEarnings | -4.38M | -2.72M | -3.42M | -4.31M |
| RetainedEarnings | -197.81M | -194.35M | -189.51M | -184.36M |
| AdditionalPaidInCapital | 206.59M | 203.21M | 200.90M | 197.37M |
| CapitalStock | 0.00 | 0.00 | 5.00K | 2.00K |
| CommonStock | 0.00 | 0.00 | 5.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 9.28M | 8.60M | 8.25M | 10.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.19M | 4.88M | 4.54M | 4.33M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 5.14M | 4.71M | 4.24M | 3.84M |
| NonCurrentDeferredLiabilities | 17.00K | 87.00K | 140.00K | 182.00K |
| NonCurrentDeferredRevenue | 17.00K | 87.00K | 140.00K | 182.00K |
| LongTermDebtAndCapitalLeaseObligation | 27.00K | 87.00K | 162.00K | 309.00K |
| LongTermCapitalLeaseObligation | 27.00K | 87.00K | 162.00K | 309.00K |
| LongTermDebt | 1.31M | |||
| CurrentLiabilities | 4.10M | 3.72M | 3.72M | 5.82M |
| OtherCurrentLiabilities | 487.00K | 694.00K | 566.00K | 784.00K |
| CurrentDeferredLiabilities | 641.00K | 478.00K | 160.00K | 1.28M |
| CurrentDeferredRevenue | 641.00K | 478.00K | 160.00K | 1.28M |
| CurrentDebtAndCapitalLeaseObligation | 278.00K | 521.00K | 687.00K | 1.06M |
| CurrentCapitalLeaseObligation | 58.00K | 198.00K | 256.00K | 250.00K |
| CurrentDebt | 220.00K | 323.00K | 431.00K | 808.00K |
| OtherCurrentBorrowings | 323.00K | 431.00K | 808.00K | 596.00K |
| CurrentNotesPayable | 220.00K | 323.00K | 431.00K | |
| PayablesAndAccruedExpenses | 2.69M | 2.03M | 2.30M | 2.70M |
| CurrentAccruedExpenses | 1.74M | 1.42M | 1.46M | 1.06M |
| Payables | 953.00K | 607.00K | 841.00K | 1.64M |
| AccountsPayable | 953.00K | 607.00K | 841.00K | 1.64M |
| TotalAssets | 13.69M | 14.74M | 16.23M | 18.84M |
| TotalNonCurrentAssets | 1.04M | 2.19M | 2.43M | 2.42M |
| OtherNonCurrentAssets | 74.00K | 66.00K | 73.00K | 77.00K |
| NonCurrentDeferredAssets | 662.00K | 1.48M | 1.45M | 1.46M |
| NonCurrentDeferredTaxesAssets | 589.00K | 1.15M | 949.00K | 829.00K |
| NetPPE | 309.00K | 651.00K | 906.00K | 879.00K |
| AccumulatedDepreciation | -2.08M | -2.38M | -2.01M | -1.71M |
| GrossPPE | 2.38M | 3.03M | 2.92M | 2.59M |
| Leases | 491.00K | 605.00K | 554.00K | 503.00K |
| OtherProperties | 1.55M | 2.06M | 2.04M | 1.84M |
| MachineryFurnitureEquipment | 338.00K | 364.00K | 324.00K | 247.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 12.65M | 12.55M | 13.80M | 16.43M |
| OtherCurrentAssets | 148.00K | 105.00K | 25.00K | 620.00K |
| CurrentDeferredAssets | 212.00K | 262.00K | 240.00K | 218.00K |
| PrepaidAssets | 236.00K | 340.00K | 438.00K | 755.00K |
| Inventory | 2.92M | 2.72M | 2.86M | 2.66M |
| InventoriesAdjustmentsAllowances | -298.00K | -296.00K | -236.00K | |
| FinishedGoods | 1.82M | 1.21M | 1.33M | 1.04M |
| RawMaterials | 1.40M | 1.80M | 1.76M | 1.63M |
| Receivables | 3.76M | 5.99M | 6.42M | 4.78M |
| TaxesReceivable | 1.53M | 3.10M | 3.85M | 2.37M |
| AccountsReceivable | 2.23M | 2.90M | 2.57M | 2.41M |
| AllowanceForDoubtfulAccountsReceivable | -8.00K | -27.00K | -16.00K | -81.00K |
| GrossAccountsReceivable | 2.24M | 2.92M | 2.59M | 2.49M |
| CashCashEquivalentsAndShortTermInvestments | 5.37M | 3.13M | 3.82M | 7.40M |
| CashAndCashEquivalents | 5.37M | 3.13M | 3.82M | 7.40M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -168.00K | -2.40M | -6.42M | -4.38M |
| RepurchaseOfCapitalStock | -1.00K | 0.00 | ||
| RepaymentOfDebt | -404.00K | -481.00K | -894.00K | -497.00K |
| IssuanceOfDebt | 515.00K | 123.00K | 1.50M | |
| IssuanceOfCapitalStock | 3.08M | 1.78M | 2.87M | 7.55M |
| CapitalExpenditure | -80.00K | -2.00K | -269.00K | -137.00K |
| InterestPaidSupplementalData | 11.00K | 22.00K | 17.00K | 24.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 767.00K | 941.00K | |
| EndCashPosition | 5.37M | 3.13M | 3.82M | 7.40M |
| BeginningCashPosition | 3.13M | 3.82M | 7.40M | 4.22M |
| EffectOfExchangeRateChanges | -616.00K | 32.00K | 345.00K | 127.00K |
| ChangesInCash | 2.86M | -724.00K | -3.92M | 3.05M |
| FinancingCashFlow | 3.03M | 1.68M | 2.49M | 7.40M |
| CashFlowFromContinuingFinancingActivities | 3.03M | 1.68M | 2.49M | 7.40M |
| NetOtherFinancingCharges | 274.00K | 373.00K | 515.00K | |
| ProceedsFromStockOptionExercised | 82.00K | 0.00 | 0.00 | 216.00K |
| NetCommonStockIssuance | 3.08M | 1.78M | 2.87M | 7.55M |
| CommonStockPayments | -1.00K | 0.00 | ||
| CommonStockIssuance | 3.08M | 1.78M | 2.87M | 7.55M |
| NetIssuancePaymentsOfDebt | -404.00K | -481.00K | -894.00K | -374.00K |
| NetShortTermDebtIssuance | -404.00K | -481.00K | -774.00K | -374.00K |
| ShortTermDebtPayments | -404.00K | -481.00K | -774.00K | -497.00K |
| ShortTermDebtIssuance | 515.00K | 123.00K | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | -120.00K | -467.00K | 1.50M |
| LongTermDebtPayments | 0.00 | -120.00K | -467.00K | 0.00 |
| LongTermDebtIssuance | 0.00 | 1.50M | ||
| InvestingCashFlow | -80.00K | -2.00K | -258.00K | -99.00K |
| CashFlowFromContinuingInvestingActivities | -80.00K | -2.00K | -258.00K | -99.00K |
| NetOtherInvestingChanges | 15.00K | 11.00K | 38.00K | -43.00K |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | 0.00 | 610.00K | ||
| SaleOfIntangibles | 0.00 | 610.00K | ||
| NetPPEPurchaseAndSale | -80.00K | -2.00K | -269.00K | -137.00K |
| PurchaseOfPPE | -80.00K | -2.00K | -269.00K | -137.00K |
| OperatingCashFlow | -88.00K | -2.40M | -6.15M | -4.25M |
| CashFlowFromContinuingOperatingActivities | -88.00K | -2.40M | -6.15M | -4.25M |
| ChangeInWorkingCapital | 2.48M | 1.69M | -1.93M | 3.13M |
| ChangeInOtherWorkingCapital | 375.00K | 577.00K | -1.11M | 1.06M |
| ChangeInOtherCurrentLiabilities | -174.00K | -161.00K | -173.00K | -222.00K |
| ChangeInPayablesAndAccruedExpense | 1.14M | 216.00K | -341.00K | 882.00K |
| ChangeInAccruedExpense | 295.00K | 19.00K | 127.00K | 679.00K |
| ChangeInPayable | 848.00K | 197.00K | -468.00K | 203.00K |
| ChangeInAccountPayable | 416.00K | -278.00K | -864.00K | -157.00K |
| ChangeInTaxPayable | 432.00K | 475.00K | 396.00K | 360.00K |
| ChangeInIncomeTaxPayable | 432.00K | 475.00K | 396.00K | 360.00K |
| ChangeInPrepaidAssets | 1.09M | 1.11M | -306.00K | -460.00K |
| ChangeInInventory | -388.00K | 184.00K | 0.00 | -100.00K |
| ChangeInReceivables | 434.00K | -230.00K | -4.00K | 1.97M |
| ChangesInAccountReceivables | 434.00K | -230.00K | -4.00K | 1.97M |
| OtherNonCashItems | 174.00K | 161.00K | 173.00K | 223.00K |
| StockBasedCompensation | 224.00K | 516.00K | 669.00K | 382.00K |
| ProvisionandWriteOffofAssets | -66.00K | -1.53M | -644.00K | |
| DeferredTax | 357.00K | -109.00K | -37.00K | -829.00K |
| DeferredIncomeTax | 357.00K | -109.00K | -37.00K | -829.00K |
| DepreciationAmortizationDepletion | 138.00K | 176.00K | 125.00K | 186.00K |
| DepreciationAndAmortization | 138.00K | 176.00K | 125.00K | 186.00K |
| Depreciation | 138.00K | 176.00K | 125.00K | 186.00K |
| OperatingGainsLosses | -1.00K | -723.00K | -770.00K | |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -3.46M | -4.83M | -5.15M | -5.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SNOA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|